The relationship between PLK1 sustained expression following HER2 therapy and fibroblasts was further examined using a publicly available transcriptomic dataset from the TRIO-US B07 clinical trial of HER2 + breast cancer patients treated with HER2-targeted therapies (n = 89 pre-/post-therapy tumors with transcriptomic data [38]). The gene discussed is ERBB2; the disease is breast cancer.